ZURA BIO LTD (ZURA:NASDAQ)
$4.26 -0.05 (-1.1601%)
Analysed ZURA BIO LTD (ZURA:NASDAQ) News Sources
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
25-02-2026
fool.com
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
27-02-2026
yahoo.com
Zura Bio to Participate in Upcoming Investor Conferences
02-03-2026
yahoo.com
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
05-03-2026
yahoo.com
UniFirst, Elastic NV, and More Stocks See Action From Activist Investors
07-03-2026
yahoo.com
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
19-03-2026
yahoo.com
One Zura Bio Insider Raised Their Stake In The Previous Year
23-04-2026
yahoo.com
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
07-05-2026
yahoo.com
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
13-05-2026
yahoo.com
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
14-05-2026
yahoo.com
What is the current price of ZURA BIO LTD (ZURA:NASDAQ)?
The current price of ZURA BIO LTD (ZURA:NASDAQ) is $4.26.
ZURA BIO LTD (ZURA:NASDAQ) absolute price change since previous trading day?
The absolute price change of ZURA BIO LTD (ZURA:NASDAQ) since the previous trading day is $-0.05.
ZURA BIO LTD (ZURA:NASDAQ) percentage price change since previous trading day?
The percentage price change of ZURA BIO LTD (ZURA:NASDAQ) since the previous trading day is -1.1601%.
What is the most recent average sentiment score for ZURA BIO LTD (ZURA:NASDAQ)?
The most recent average sentiment score for ZURA BIO LTD (ZURA:NASDAQ) is 75 out of 100.
What is the most recent average sentiment for ZURA BIO LTD (ZURA:NASDAQ)?
The most recent sentiment for ZURA BIO LTD (ZURA:NASDAQ) is .
SEC-8K** Filing Available For ZURA BIO LTD (ZURA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.